Subscribe to The Post Most newsletter for the most important and interesting stories from The Washington Post. The Trump ...

The decision by the Center for Disease Control and Prevention to stop recommending giving infants a dose of the hepatitis B ...

The revised guidelines also will lead to more than $20 million in extra health care costs, the research shows.

Two new studies published this week in the Journal of the American Medical Association (JAMA) demonstrate that delaying ...

The World Health Organization (WHO) released a new report on hepatitis today, marking the World Hepatitis Summit. Since 2015, ...

Phase 3 trial results demonstrate that bepirovirsen significantly increases the proportion of patients achieving functional cure compared with placebo.

HBV infection at birth or during early infancy can lead to lifelong health problems such as chronic liver disease and liver ...

About 90% of infants infected at birth go on to develop chronic infection ...

Hepatitis B virus (HBV) infection acquired at birth or during early infancy can lead to lifelong health complications, ...

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the ...

New studies warn delaying the hepatitis B birth dose could leave more babies vulnerable to infection and long-term illness.

GSK (GSK) announced on Tuesday that the U.S. Food and Drug Administration (FDA) granted priority review for its marketing application for bepirovirsen, a hepatitis B therapy licensed from Ionis ...